The pathologies of many infectious, autoimmune and malignant diseases are influenced by the profiles of cytokine production in pro-inflammatory (TH1) and anti-inflammatory (TH2) T cells. Interindividual differences in cytokine profiles appear to be due, at least in part, to allelic polymorphism within regulatory regions of cytokine gene. Many studies have examined the relationship between cytokine gene polymorphism, cytokine gene expression in vitro, and the susceptibility to and clinical severity of diseases. A review of the findings of these studies is presented. An on-line version featuring appropriate updates is accessible from the World Wide Web site, http://www.pam.bris.ac.uk/services/GAI/cytokine4.htm.
Introduction: cytokines, the cytokine network and the Th1-Th2 paradigm
Cytokines are humoral immunomodulatory proteins or glycoproteins which control or modulate the activities of target cells, generally those within the haematopoietic system. They act on target cells by binding to specific cytokine receptor ligands, initiating signal transduction and second messenger pathways within the target cell. [1] [2] [3] [4] [5] This can result in gene activation, leading to mitotic division, growth and differentiation, migration, or apoptosis.
Cytokines are produced by a wide range of cell types and have been broadly classified as monokines (produced by cells of the monocyte lineage) or lymphokines (produced by lymphocytes), though this is arguably an over-simplistic classification: other classifications are based on functional or structural groupings. 6, 7 Cytokines act in a highly complex coordinated network in which they induce or repress their own synthesis as well as that of other cytokines and cytokine receptors. In addition, many cytokines appear to be pleiotropic, with the cor-ollary that the cytokine network is highly flexible, since there is considerable overlap and redundancy between the function of individual cytokines. [8] [9] [10] [11] [12] This feature continues to complicate efforts to analyse both the function of individual cyokines and the influence of cytokine gene polymorphism on gene expression and disease.
Cytokine production by the cells of the immune system may occur through antigen-specific and non-antigen specific stimuli. For example, monocytes when exposed to bacterial cell wall products, such as lipopolysaccharide, produce IL-12 and other cytokines which have multiple functions including influencing the expression of cytokines by other cells. Antigen-specific responses are generated by B and T cells through immunoglobulin and T cell receptors respectively. B cell activation may result in the production of IL-6 and other cytokines. T cells are central players in linking non-antigen specific, B cell and T cell responses together. Two classes of T cells are recognized: ␣,␤ and ␥,␦ T cells, defined by their T cell receptor (TCR) chain usage. The majority of circulating ␣,␤ T cells carry either CD4 or CD8 molecules, which bind to MHC class II or MHC class I molecules, respectively. The ligand of ␥,␦ T cells is not clearly known, and these cells typically carry neither CD4 nor CD8 molecules, hence the name 'double negative' T cells. Functionally, CD8+ T cells, are typically cytotoxic T cells and can kill target cells presenting processed foreign peptide via HLA class I molecules; some CD8+ T cells secrete cytokines such as IFN␥. CD4+ T cells are typically helper T cells, although rare subsets have cytoxic function. Several TH subsets of CD4+ T cells have been identified. In the mouse these subsets are well defined and include Type 1 (TH1), which promote cell-mediated effector responses; and Type 2 CD4+ helper T cells (TH2), which promote B cellmediated humoral responses. Cytokines produced by TH1 cells include interleukin-2 (IL-2), interferon gamma (IFN␥) and tumour necrosis factor beta (TNF␤), and constitute a pro-inflammatory cytokine profile; those produced by TH2 cells include IL-4, IL-5, IL-6, and IL-10, ie, a predominantly anti-inflammatory cytokine profile. Both TH1 and TH2 cells produce IL-3 and granulocyte-macrophage colony stimulating factor (GM-CSF). [13] [14] [15] [16] [17] [18] [19] [20] Recently a TH3 subset (characterized by TGF␤) has been defined. In humans, the distinction between TH1, TH2 and TH3 is less well defined, and a subset of TH0 cells, which produce some cytokines typical of TH1 and TH2 profiles can be identified. The clinical outcome of many infectious, autoimmune, or malignant diseases appears to be influenced by the overall balance of production (profiles) of pro-inflammatory and anti-inflammatory cytokines. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Hence, much interest has focused upon the regulation of genes expressing these cytokines. In particular, a significant number of studies have addressed whether genetic polymorphism within these genes might influence the levels of expression, and therefore the overall immune response. A review of the findings of these studies is presented here.
Cytokine gene polymorphism: influence on protein structure, expression and disease
Cytokine gene polymorphism Non-conservative mutation within the coding region of genes can result in loss, abrogation, or change of function in the expressed protein as a result of change in protein structure. Cytokine and cytokine receptor genes are generally highly conserved in terms of exon sequences, 32, 33 although examples of amino acid sequence variation have been found for IL-4 receptor, LT␣ (TNF␤), TGF␤ and GM-CSF receptor ␤ in healthy individuals; and in the IL-2 receptor ␥ gene for persons with severe combined immunodeficiency (Tables 1 and 3 ). Although conservative (silent) mutations do not affect amino acid sequence, they may influence protein expression in a variety of other ways: for example, they can alter mRNA splicing, mRNA stability, and levels of gene transcription. Polymorphisms within the 5Ј-and 3Ј-regulatory sequences or introns of genes may have a significant effect on transcription, since they may alter the structure of transcription factor binding sites within gene promoters or the structure of enhancers and silencers within introns or at more remote regulatory sites. Finally, they may alter binding sites within the nuclear matrix for architectural transcription factors which modulate promoter geometry. 34 Many of the reported polymorphisms within cytokine genes occur within known or putative regulatory regions 32, 33 (Table 1) . The rationale for studying cytokine gene polymorphisms in human disease can be broadly summarised as follows: • To enhance the understanding of the aetiology and pathology of human disease.
• To identify potential markers of susceptibility, severity, and clinical outcome.
• To identify potential markers for responders vs nonresponders in therapeutic trials.
• To identify targets for therapeutic intervention.
• To identify novel strategies to prevent disease or to improve existing preventions such as vaccines.
The influence of cytokine gene polymorphisms on gene expression and disease has been addressed at two levels of research: studies using in vitro gene expression, and those involving in vivo disease association. Only a few studies have thus far integrated both of these approaches.
In vitro gene expression studies
Up-regulated and/or down-regulated expression and production of cytokine mRNA and cytokines, or of their receptors, is a feature in most immune responses in human diseases. However, this response may differ significantly among individuals. In vitro gene expression studies attempt to determine a genetic basis for interindividual differences in the immune response. This is achieved by examining the relationship between individual polymorphic alleles or haplotypes of cytokine genes and the expression of the transcript or cytokine in vitro. The main approaches used to date include measuring the levels of cytokine or cytokine receptor mRNA, or of cytokine or receptor protein, expressed as a result of in vitro stimulation of cells in culture with a mitogen; and isolation of individual alleles of gene promoters by cloning adjacent to a reporter gene in an expression vector, followed by transfection of an appropriate cell line and measurement of reporter protein expression. The majority of studies to date have followed the first approach. It is becoming increasingly apparent that the results of expression stud- ies may be critically influenced by several factors such as the cell lineage used in the assay and the therapeutic preconditioning or treatment of subjects prior to harvesting cells for the assay. Therefore, the reader should refer to publications of individual studies in which apparent contradictions between results are evident. A review of the results of the principal studies is shown in Table 2 .
In vivo disease association studies
These studies attempt to identify immunogenetic markers for a given disease. Association is sought between specific cytokine gene polymorphisms and clinical outcome by direct comparison of individual cytokine genotypes and the clinical features of the disease (eg, susceptibility, duration and severity). The a priori involvement of dysregulation of a specific cytokine or receptor in the disease is usually, though not always, the rationale for selecting a cytokine or cytokine receptor gene for analysis. Such data may be generated using population-based or family studies in humans or using animal models, and may be from analysis of secreted, cell surface or intracellular protein, or of cytokine mRNA. Using these and other clues, many studies have identified statistically significant associations between cytokine alleles and disease. However, in many of these studies the in vitro expression studies have not been attempted, or are the subject of controversy, or by consensus have not indicated a convincing functional rationale for the association. The genetic analysis of cytokines in human disease has traditionally focused on case-control association studies, in which the frequencies of marker alleles in groups of patients and healthy controls are compared, and the difference is subjected to statistical analysis. The association is often expressed as the relative risk (or odds ratio) that an individual will develop the disorder if he or she carries the particular allele or marker, compared to an individual who does not carry the allele or marker. These studies have met with only modest success in identifying disease-causing cytokine genes, in part because of the difficulty in selecting from among the many candidate possibilities, and the likely modest effect of any single disease susceptibility gene. The difficulty in identifying a perfectly matched control group creates an additional limitation, increasing the possibility that a potentially positive association is biologically irrelevant because of population admixture. Furthermore, even when cases and controls are adequately matched, most study designs involve relatively small sample sizes which lack the statistical power to detect small or moderate gene effects. Other approaches to identifying associations between complex traits and cytokine or cytokine receptor gene polymorphism use a variety of family-based study designs. These include whole genome scanning using linkage analysis (LOD scores) and affected sib-pair (ASP) methods. With identification of specific chromosomal regions, more precise localisation required the development of linkage disequilibrium mapping 35 and transmission disequilibrium testing 36, 37 with the establishment of ancestral haplotypes among disease-associated chromosomes. 38 Allelic association methods based on increased transmission of marker alleles will need to be employed for the mapping of complex disease susceptibility genes. However, because the extent of association of single marker alleles with disease is a function of the relative frequency of the allele on disease-associated chromosomes vs non disease-predisposing chromosomes, the most associated marker allele in a region will not necessarily be closest to the disease locus. Although this area is controversial, the extended transmission/disequilbrium test (TDT) 37 may be best approach. 39 While combined analysis of data from several studies can be pooled to increase confidence in the strength of observed associations, biases in reporting positive or weak associations as opposed to lack of reporting negative associations also influences interpretation of published observations.
One of the sometimes overlooked aspects of such dis-ease association studies is that the cytokine network is highly complex, containing interactive cascades of gene activation and suppression. One consequence of mutual TH1-TH2 antagonism may be the predominance of one or the other subset, which might directly influence the clinical outcome of disease. Therefore, genetic polymorphisms in cytokine genes and their receptors which regulate expression should not in all cases be studied strictly in isolation. This is because individual associations may be non-informative, whereas specific combinations of cytokine genotypes might predispose to disease susceptibility or outcome. Only a very few studies to date have attempted to analyse the combined contribution of more than one cytokine gene polymorphism to disease. A review of the results of the principal disease association studies is shown in Table 3 , both statistically significant (scored as 'yes') and statistically non-significant (scored as 'no'). The statistical significance is recorded as interpreted by the originating authors: for details of the statistical tests and corrections used, the reader should refer to the papers cited. For certain combinations of polymorphisms and diseases, contradictory results have been published. In these cases, the discordancy may be attributable to differences in ethnicity of populations, patient and/or control cohort selection or size, disease classification or status, or methods of statistical analysis. Both in vitro expression studies and in vivo disease association studies involving TNF␣ and LT␣ (TNF␤) polymorphisms are often complicated by their linkage disequilibrium (LD) with HLA genes and haplotypes within the major histocompatibility complex. This has created difficulties in dissecting the independent role of TNF in expression and disease (see Table 2 and 3 for examples). Tables 1, 2 and 3 and associated citations are reproduced in electronic form on the World Wide Web. They are searchable using the appropriate 'find' command of Web browsers. It is the intention of the authors to issue regular updates of these tables as part of an ongoing feature of this Journal. Notification and details of the revisions to the tables will be published as appropriate.
On-line databases
The Web site URL for Tables 1, 2 and 3 and associated  citations is: http://www.pam.bris.ac.uk/services/GAI/cytokine4.htm
Cytokine reviews database
In addition to these databases, we have issued a searchable reference database containing 1000 cytokine review citations, from 1990 to the present. This database is provided in two formats:
• Endnote™ version 3 (filename CYTOREVIEWS.ENL) • Tagged MEDLARS format (.TAG) file (filename CYTOREVIEWS.TAG)
The files contain both general and disease-specific reviews relating to cytokines and cytokine receptors. The Endnote version may be searched using any criteria available within the Endnote™ application, eg, by author or keyword. The tagged MEDLARS version may be imported directly into other reference manager programs. Both files may be downloaded directly from the Web site shown above. 64 approached the measurement of IL-6 production in their control subjects, demonstrates the importance of the natural metabolic variation which occurs daily. This supported earlier studies, for example that of Petrovsky and Harrison, 313 who showed that the LPs induction of IL-10 and IFN-gamma varied throughout the day, observing that the IFN-gamma/IL-10 ratio peaked early in the morning and concluding that both cortisol and melatonin could regulate diurnal immune variation. Although much has been made of the requirement for caution when interpreting genetic data from the TNF cluster without due consideration of the MHC and linkage disequilibrium, MHC effects on cytokines off chromosome 6 have not been so well documented. The evidence is beginning to emerge, however. A study in 1997 314 demonstrated that secreted levels of IFN-gamma varied markedly with class-II alleles, in an MLR. DR1, DR2 and DR6 were associated with high IFN-gamma secretion while DR3, DR4 and DR7 were associated with lower IFN-gamma production. Similar conclusions were drawn for those DQ alleles in linkage disequilibrium with the DR alleles noted above. This pattern was reversed for TNF secretion (ie, DR3 was high TNF and so on), mirroring earlier work by Pociot et al 115 who demonstrated a DR-based hierarchy of TNF secretion which was of greater magnitude than the TNF-allele results for which they are more usually remembered. Similar data are available for other aspects of the immune system, for example antibody production. 315 In this regard, DR3 has received the greatest attention. T cell activation varies in DR3-positive individuals, perhaps because of diminished CD69 expression, 316 as do cytokines themselves 317 particularly in regard to autoimmune DR3 positive subjects. 318 Apoptosis may differ because these individuals have diminished expression of CD95 (FAS 319 ) and indeed lower total lymphocyte counts have been described in aassociation with B8-DR3. 320 Little insight to the mechanism of these various effects by the class-II on immune function was available until recently, when it was demonstrated that different class-II molecules varied in the efficiency with which they transduce signals from CD4 across the cell membrane, and that this variation is carried with the intracellular portion of the class-II molecule. 321 As if this were not confusing enough, the age of the donors themselves has been shown to affect T cell activation 322, 323 through various mechanisms. In conclusion, the genetic effect seen to be acting on cytokine production, and implicating them as disease-associated loci in their own right, are complicated by the MHC and age.
Related World Wide Web sites
How well we as a research community deal with these complications will determine how efficiently the influence of cytokine immunogenetics on disease is elucidated.
